Chas­ing Bio­gen, the Pli­ant crew banks a $62M round to fu­el their shot at fi­bro­sis tar­gets

South San Fran­cis­co-based Pli­ant Ther­a­peu­tics has just closed a $62 mil­lion round to take their id­io­path­ic pul­monary fi­bro­sis drug to the clin­ic — the first of many fi­brot­ic dis­ease-tar­get­ing drugs it hopes will come out of its dis­cov­ery en­gine.

The Se­ries B puts Pli­ant in a po­si­tion to progress to­ward clin­i­cal proof of con­cept for its lead small mol­e­cule drug, which is a dual in­hibitor of the αvβ1 and αvβ6 in­te­grins. As a fam­i­ly of trans­mem­brane re­cep­tors that usu­al­ly me­di­ate cell ad­he­sion, in­te­grins — as sci­en­tif­ic co-founder Dean Shep­pard has shown in his work at UCSF — are a key dri­ver in fi­bro­sis across dif­fer­ent or­gans.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.